Tirzepatide Efficacy Predictors Identified: Clinical, Genetic, and Molecular Biomarkers Guide Precision Medicine

Despite Tirzepatide's robust efficacy in managing Type 2 Diabetes Mellitus (T2DM) and obesity through its dual GLP-1 and GIP receptor agonism, significant interindividual variability in treatment response is observed. This variability poses a challenge for optimizing patient outcomes and necessitates a precision medicine approach. Understanding the specific factors that predict response is crucial for tailoring therapy, identifying potential non-responders early, and maximizing the therapeutic benefits across diverse patient populations.

This narrative review systematically summarized current evidence on clinical, genetic, and molecular predictors of Tirzepatide response. Researchers evaluated data from pivotal clinical trials, post hoc analyses, and other relevant preclinical and clinical studies. The aim was to identify determinants of glycemic control, weight loss, and organ-protective effects, specifically focusing on hepatic and renal outcomes. The methodology involved synthesizing existing literature to build a comprehensive framework for understanding response variability.

The review identified a multidimensional array of predictors for Tirzepatide efficacy. Key clinical factors included Tirzepatide dose, duration of diabetes, baseline β-cell function, baseline glycated hemoglobin, sex, age, race, concomitant therapies, and early treatment response. Genetic factors implicated in response variability included variants in GLP-1R, GIPR, β-arrestin 1, TCF7L2, FTO, and MC4R, though Tirzepatide-specific validation for these remains limited. Molecular biomarkers showing potential as pharmacodynamic indicators of metabolic response included branched-chain amino acids, IGFBP-1 and -2, the adiponectin-to-leptin ratio, high-sensitivity C-reactive protein, and IL-6.

For organ-specific outcomes, procollagen type III N-terminal peptide and magnetic resonance imaging-proton density fat fraction are supported for assessing hepatoprotective effects, while cystatin C-based estimated glomerular filtration rate and urine albumin-to-creatinine ratio are validated markers of renoprotection. Additional candidates like TNF receptor 1/2, kidney injury molecule-1, and neutrophil gelatinase-associated lipocalin are promising but require prospective validation.